FDA: Possible link between CellCept and Myfortic and Progressive Multifocal Leukoencephalopathy (PML) disease
Audience: Transplantation specialists, infectious disease specialists, other healthcare professionals
April 10, 2008--FDA informed healthcare professionals that the Agency is investigating a potential association between the use of CellCept and Myfortic, medicines used to prevent organ rejection, and the development of progressive multifocal leukoencephalopathy (PML), a life-threatening disease.
PML is a rare disorder that affects the central nervous system usually occurring in patients with immune systems suppressed by disease or medicines.
FDA is reviewing data submitted by Roche, including postmarketing reports it has received of PML in patients who took CellCept or Myfortic, and the proposed revisions to the CellCept prescribing information.
FDA has asked Novartis, the maker of Myfortic, for data on PML cases and to revise the Myfortic prescribing information to include the same information about PML included in the CellCept prescribing information.
FDA anticipates it may take about 2 months to complete its review of the postmarketing reports and the proposed revisions to the prescribing information.
As soon as the review is completed, FDA will communicate the conclusions and recommendations to the public.
Until further information is available, patients and healthcare professionals should be aware of the possibility of PML, such as localized neurologic signs and symptoms in the setting of a suppressed immune system, including during therapy with CellCept and Myfortic.
see also:
CellCept Update
Additional warning included in the June 2008 FDA update about CellCeptThis June 2008 update from the FDA further warns about CellCept
Beverages
Bolthouse Farms Recalls Carrot Juice due to Botulism ConcernBolthouse Farms Voluntarily Recalls Carrot Juice as Precaution
Health Alerts
Health Alert: FDA Recalls Spinach after E. Coli OutbreakHealth Alert: Breaking News--FDA Recalls Spinach after E.Coli Outbreak
